Dr. Claus Vielsack appointed member of the management board of STRATEC for Product Development

STRATEC Biomedical AG / Key word(s): Change of Personnel

17.02.2014 / 10:04

Dr. Claus Vielsack appointed member of the management board of STRATEC for Product Development

Birkenfeld, February 17, 2014

STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) announces the appointment of Dr. Claus Vielsack (46) to the Board of Management of STRATEC as Product Development Director, effective February 15, 2014. Dr. Vielsack expands the current Board of Management, comprising Marcus Wolfinger, Dr. Robert Siegle and Bernd M. Steidle, and will be responsible for the group-wide management of product development, an area for which he has borne responsibility since 2011 in his capacity as Senior Vice President.

Dr. Vielsack has held various senior product development positions at STRATEC since 1998. Before joining STRATEC, he held a number of different positions working as a program manager in the development of chemical applications and software solutions. Dr. Vielsack holds a degree in chemistry from the University of Konstanz, where he also obtained his doctorate in physical chemistry.

Marcus Wolfinger, Chairman of the Board of Management of STRATEC Biomedical AG: 'The appointment of Dr. Claus Vielsack as Development Director underlines the importance this company division has for the further growth of the STRATEC Group. Claus Vielsack has worked at STRATEC in various senior positions within product development for more than 15 years now. He is a respected colleague and enjoys the utmost trust among our customers and partners. His all-round understanding of the latest technologies and developments in our industry is already reflected in numerous product solutions in place at our partners. We are therefore delighted to welcome Dr. Vielsack to the Board of Management.'

Comments Dr. Claus Vielsack: 'I look forward to working together with a highly motivated, internationally proven team to help shape our company's future. STRATEC is consistently expanding its development activities at various locations to enable us to offer our partners ideal solutions along the entire value chain. STRATEC's growing market share and the great trust placed in the company by leading diagnostics players are also reflected in the major development projects recently acquired. These in turn will underpin STRATEC's future growth.'

Note for media: A photograph of Dr. Claus Vielsack for editorial use can be found on the internet at www.stratec.com > STRATEC Group > News & Media > Press Pictures > Board of Management.

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999

End of Corporate News

17.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

252785  17.02.2014